What is the recommended management for chronic focal ileus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment for Chronic Focal Ileus

For chronic focal ileus, treatment should be directed at the underlying cause when identifiable, combined with symptom-targeted pharmacological management including prokinetics (prucalopride), antimuscarinics for pain, antibiotics for bacterial overgrowth, and nutritional support with home parenteral nutrition (HPN) when oral/enteral intake is inadequate. 1

Algorithmic Approach to Management

Step 1: Identify and Treat Underlying Conditions

The first priority is addressing any treatable underlying disease 1:

  • Connective tissue disorders, enteric myositis, neoplastic disease: May require immunosuppressive therapy (prednisolone, ciclosporin have shown benefit in autoimmune myopathy)
  • Diabetes: Optimize control aggressively, potentially with insulin pump
  • Electrolyte/endocrine abnormalities: Prevent and correct promptly
  • Bacterial overgrowth: Treat with rotating antibiotics (amoxicillin-clavulanic acid, ciprofloxacin, metronidazole, rifaximin) 1

Step 2: Symptom-Targeted Pharmacological Management

The drug therapy targets the patient's most bothersome symptom, even if medications have conflicting actions 1:

For Dysmotility/Constipation:

  • Prucalopride (5-HT4 agonist): The preferred prokinetic now that cisapride and tegaserod are withdrawn. Enhances acetylcholine release, improves transit 1
  • Linaclotide: Acts on guanylate cyclase-C, increases luminal fluid secretion and accelerates transit, may have visceral analgesic properties 1
  • Methylnaltrexone or naloxegol: For opioid-induced constipation specifically, peripherally acting mu-opioid antagonists that don't affect central analgesia 1
  • Osmotic laxatives, stimulant suppositories, enemas: Progress from phosphate enemas to high-volume saline washouts or transanal irrigation if needed 1

Critical caveat: Avoid domperidone and metoclopramide for long-term use due to QTc prolongation and tardive dyskinesia risks 1

For Colicky Pain:

  • Dietary modification first: Reduce fiber to decrease bacterial fermentation and gas production; consider low FODMAP diet (but avoid in malnourished patients) 1
  • Peppermint oil: Simple initial measure 1
  • Antimuscarinics:
    • Hyoscine butylbromide (poorly absorbed orally; intramuscular preparations more effective for long-term home use)
    • Dicycloverine hydrochloride
    • Propantheline bromide 1
  • Pregabalin, low-dose opioids for severe refractory pain 1

For Vomiting:

  • Ondansetron (5-HT3 antagonist): First-line now that domperidone/metoclopramide are contraindicated long-term (note: can worsen constipation) 1
  • Venting gastrostomy (≥20 French gauge): If nasogastric drainage helps, consider endoscopic/radiological gastrostomy for decompression. Be aware of complications (leakage, infection) 1

Step 3: Nutritional Support

Home Parenteral Nutrition (HPN) is life-saving and should be initiated when patients cannot meet nutritional requirements orally/enterally 2, 3:

  • Grade B recommendation for chronic intestinal failure from non-malignant disease 2
  • Consider if unable to tolerate adequate oral intake for >7 days post-operatively 4
  • Requires specialized multidisciplinary management and expertise 3

Step 4: Surgical Considerations

Surgery should be highly selective and avoided in most cases 1, 5:

  • Avoid colectomy for these patients—outcomes are poor 1
  • Defunctioning loop ileostomy (reversible) may be considered before total colectomy 1
  • Manual evacuation under anesthesia only if disimpaction fails after oral/rectal treatment 1
  • Intestinal transplantation is rescue therapy only for intestinal failure patients unsuitable for or unable to continue HPN 5, 3

Key Pitfalls to Avoid

  1. Don't use prokinetics after bowel anastomosis 1
  2. Don't perform colectomy for constipation in dysmotility patients—outcomes are universally poor 1
  3. Don't use metoclopramide long-term due to irreversible tardive dyskinesia risk, especially in elderly 1
  4. Don't delay HPN in patients with chronic intestinal failure—it's life-saving, not optional 2, 3
  5. Don't use restrictive diets (low FODMAP) in already malnourished patients 1

Evidence Quality Note

The evidence base for chronic intestinal dysmotility management is predominantly low quality (case series, expert opinion), with only 12% of literature consisting of controlled studies 3. However, the 2020 Gut guidelines 1 represent the most comprehensive and recent expert consensus, supported by the 2016 ESPEN guidelines on chronic intestinal failure 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.